Eli Lilly And Co (NYSE:LLY) Shares Bought by NJ State Employees Deferred Compensation Plan

NJ State Employees Deferred Compensation Plan grew its position in Eli Lilly And Co (NYSE:LLY) by 19.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,560 shares of the company’s stock after buying an additional 4,600 shares during the quarter. NJ State Employees Deferred Compensation Plan’s holdings in Eli Lilly And Co were worth $3,194,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in LLY. Vanguard Group Inc. boosted its stake in shares of Eli Lilly And Co by 0.8% during the second quarter. Vanguard Group Inc. now owns 71,134,378 shares of the company’s stock valued at $7,880,977,000 after acquiring an additional 578,045 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly And Co by 1.5% during the second quarter. BlackRock Inc. now owns 61,979,145 shares of the company’s stock valued at $6,866,670,000 after acquiring an additional 898,845 shares during the last quarter. Northern Trust Corp boosted its stake in shares of Eli Lilly And Co by 0.3% during the second quarter. Northern Trust Corp now owns 11,056,098 shares of the company’s stock valued at $1,224,906,000 after acquiring an additional 32,421 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Eli Lilly And Co by 20,030.9% during the second quarter. Nuveen Asset Management LLC now owns 7,265,844 shares of the company’s stock valued at $804,983,000 after acquiring an additional 7,229,751 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. boosted its stake in shares of Eli Lilly And Co by 13.2% during the second quarter. Amundi Pioneer Asset Management Inc. now owns 5,422,106 shares of the company’s stock valued at $600,715,000 after acquiring an additional 632,573 shares during the last quarter. Institutional investors and hedge funds own 77.22% of the company’s stock.

A number of analysts recently commented on LLY shares. Bank of America started coverage on Eli Lilly And Co in a research note on Wednesday, October 16th. They set a “buy” rating and a $133.00 price objective on the stock. UBS Group decreased their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating on the stock in a research note on Thursday, October 17th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Eli Lilly And Co presently has a consensus rating of “Buy” and an average price target of $130.03.

NYSE:LLY traded up $0.76 during mid-day trading on Friday, reaching $113.53. The company’s stock had a trading volume of 2,190,598 shares, compared to its average volume of 7,683,282. The company’s fifty day simple moving average is $110.61 and its two-hundred day simple moving average is $112.67. The company has a debt-to-equity ratio of 4.09, a current ratio of 1.17 and a quick ratio of 0.88. Eli Lilly And Co has a twelve month low of $101.36 and a twelve month high of $132.13. The stock has a market cap of $106.81 billion, a P/E ratio of 20.46, a P/E/G ratio of 1.82 and a beta of 0.16.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 23rd. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The firm had revenue of $5.48 billion for the quarter, compared to analyst estimates of $5.50 billion. Eli Lilly And Co had a return on equity of 107.99% and a net margin of 35.10%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period last year, the company earned $1.39 EPS. Sell-side analysts expect that Eli Lilly And Co will post 5.78 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Friday, November 15th will be issued a $0.645 dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.27%. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

In other news, major shareholder Lilly Endowment Inc sold 173,918 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $114.05, for a total value of $19,835,347.90. Following the transaction, the insider now directly owns 116,229,383 shares in the company, valued at approximately $13,255,961,131.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Stephen F. Fry sold 9,452 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $115.00, for a total value of $1,086,980.00. Following the completion of the transaction, the senior vice president now owns 100,211 shares in the company, valued at $11,524,265. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 8,405 shares of company stock worth $909,004 and sold 614,373 shares worth $70,546,895. Company insiders own 0.11% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is a recession?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.